Monoclonal Antibodies
New monoclonal antibodies research has been reported by scientists at National Cancer Institute
Published in Cancer Weekly, September 2nd, 2008
"We hypothesized that the complementary inhibition of VEGF signaling would have synergistic therapeutic effects. Patients and Methods Patients had advanced solid tumors, Eastern Cooperative Oncology Group performance status of 0 to 1, and good end-organ function. A phase I dose-escalation trial of sorafenib and bevacizumab was initiated at below-recommended single-agent doses because of possible overlapping toxicity: sorafenib 200 mg orally twice daily...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-09-02)
More Articles from Cancer Weekly
- University of Rochester Medical Center
Why a common treatment for prostate cancer ultimately fails - Cancer
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine - Cancer
Hero Police Dog Succumbs to Cancer - Morris Animal Foundation Honors 'Rocky' - Also Honored 'Rocky' Six Years Ago When He Was Shot - Cancer
Prescription Sleeping Pill Use Tied to Cancer - Cancer Vaccines
Investigators at Johns Hopkins University release new data on cancer vaccines - Cancer Vaccines
New cancer vaccines findings from Jilin University described - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
